Immunity Inflammation and Disease,
Год журнала:
2024,
Номер
12(9)
Опубликована: Сен. 1, 2024
This
study
aimed
to
evaluate
six
novel
lymphocyte-based
inflammatory
markers
(neutrophil-lymphocyte
ratio,
monocyte-lymphocyte
platelet-lymphocyte
ratio
[PLR],
systemic
immune
inflammation
index
[SII],
response
index,
and
[SIIRI])
in
patients
with
newly
diagnosed
coronary
artery
disease
[CAD].
Frontiers in Cardiovascular Medicine,
Год журнала:
2024,
Номер
11
Опубликована: Июль 12, 2024
Background
Inflammation
is
considered
to
play
an
important
role
in
chronic
obstructive
pulmonary
disease
(COPD)
and
acute
myocardial
infarction
(AMI),
but
the
relationship
between
inflammation
poor
prognosis
these
patients
has
not
yet
been
studied.
Methods
We
enrolled
AMI
combined
with
COPD
divided
them
into
three
groups
according
tertiles
of
neutrophil-to-lymphocyte
ratio
(NLR),
platelet
lymphocyte
(PLR)
monocyte
(MLR)
respectively.
Logistic
regression
analyses
were
used
identify
risk
factors
for
in-hospital
all-cause
death
patients.
Covariates
adjusted
stepwise
determine
association
inflammatory
markers
prognosis.
Also,
receiver
operating
characteristic
(ROC)
curve
was
evaluate
greatest
predictive
indicator
death.
Results
A
total
281
enrolled,
which
31
experienced
mortality.
The
significantly
higher
among
those
NLR.
highest
tertile
NLR
associated
increased
(all
P
<
0.05).
This
remained
significant
after
adjusting
confounding
[Odds
Ratio
(OR):
10.571,
95%
confidence
interval
(CI):
2.307–48.442,
=
0.002].
Moreover,
compared
MLR
PLR,
had
value
[area
under
(AUC):
0.764,
CI:
0.681–0.847].
Conclusion
In
COPD,
elevated
levels
Compared
other
indicators,
may
provide
a
more
superior
value.
World Journal of Methodology,
Год журнала:
2024,
Номер
14(3)
Опубликована: Июнь 25, 2024
The
lymphocyte
to
monocyte
ratio
(LMR)
is
considered
a
marker
of
systemic
inflammation
in
cardiovascular
disease
and
acts
as
predictor
mortality
coronary
artery
disease.
Immunity Inflammation and Disease,
Год журнала:
2024,
Номер
12(9)
Опубликована: Сен. 1, 2024
This
study
aimed
to
evaluate
six
novel
lymphocyte-based
inflammatory
markers
(neutrophil-lymphocyte
ratio,
monocyte-lymphocyte
platelet-lymphocyte
ratio
[PLR],
systemic
immune
inflammation
index
[SII],
response
index,
and
[SIIRI])
in
patients
with
newly
diagnosed
coronary
artery
disease
[CAD].